轩竹生物(02575.HK) 公布,近期从中国国际经济贸易仲裁委员会获得仲裁裁决,涉及与一家生物技术公司于2021年签订的技术转让合同相关争议,该公司将特定药品在中国的上市许可及商业化销售权利独家转让予轩竹生物,其后该产品的仿制药品被纳入国家组织药品集中带量采购,实施后类似药品价格大幅下降,双方就研发成果及GMP检查进度发生争议,此前已就合同免责终止讨论惟未能和解。该公司于2024年向仲裁委提交...
Source Link轩竹生物(02575.HK) 公布,近期从中国国际经济贸易仲裁委员会获得仲裁裁决,涉及与一家生物技术公司于2021年签订的技术转让合同相关争议,该公司将特定药品在中国的上市许可及商业化销售权利独家转让予轩竹生物,其后该产品的仿制药品被纳入国家组织药品集中带量采购,实施后类似药品价格大幅下降,双方就研发成果及GMP检查进度发生争议,此前已就合同免责终止讨论惟未能和解。该公司于2024年向仲裁委提交...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.